Net earnings for the third quarter of 2008 were $3.3 billion, an increase of 29.9%, compared to $2.54 billion posted in the third quarter of 2007. Net diluted earnings per share for the third quarter of 2008 were $1.17, an increase of 33%, compared to $0.88 posted in the third quarter of 2007.
The company has reported sales of $48.5 billion for the first nine months of 2008, an increase of 7.6%, compared to $45.14 billion posted in the same period of 2007.
Net earnings for the first nine months of 2008 were $10.2 billion, an increase of 24.8%, compared to $8.2 billion posted in the same period of 2007. Net diluted earnings per share for the first nine months of 2008 were $3.6, an increase of 28.1%, compared to $2.81 posted in the same period of 2007.
William Weldon, chairman and CEO of Johnson & Johnson, said: “Johnson & Johnson continues to achieve solid earnings results despite the impact that generic products have had on our pharmaceutical business. Of note was the strong sales performance of our consumer segment and the solid sales results in our medical devices and diagnostics segment.”